PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1643595
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1643595
The global pharmaceutical analytical testing outsourcing market is poised for significant growth, with projections indicating an increase from $9.4 billion in 2024 to $18.1 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.7%. This expansion is driven by innovations in the pharmaceutical industry, heightened emphasis on safety and quality, and the cost advantages associated with outsourcing analytical testing services. The COVID-19 pandemic has further underscored the importance of these services, as outsourcing providers played a crucial role in meeting the testing demands of pharmaceutical companies and contract research organizations (CROs) worldwide.
Key Insights
Bioanalytical testing holds the largest market share, accounting for 35% in 2024, and is expected to grow at the highest pace in the coming years. The increasing complexity of in-vitro and in-vivo tests, along with changing legislation, contributes to this growth. Bioanalytical testing is essential for quantitatively identifying the characteristics of medicines and metabolites in biological matrices.
Active pharmaceutical ingredients (APIs) represent the largest product category, holding 55% of the market share in 2024. The quality of APIs directly influences the safety and efficacy of drugs, making their analysis critical. Outsourcing API analysis offers cost savings on specialized containment infrastructure and ensures compliance with stringent Good Manufacturing Practice (GMP) obligations.
North America leads the market, attributed to the rise in the number of biopharmaceutical companies and the presence of major market players. Asia-Pacific is expected to grow at the highest pace in the coming years, owing to the surging development of pharmaceutical companies focusing on the region due to low development and labor costs, improved GMP compliance, and a skilled workforce capable of performing complex drug synthesis.
The integration of advanced technologies such as automation, artificial intelligence (AI), and data analytics is transforming pharmaceutical analytical testing by enhancing efficiency and accuracy. Automation streamlines routine tasks, reducing human error, while AI algorithms process large volumes of data to identify patterns and optimize testing protocols.
The market is moderately competitive, with key players adopting strategies such as facility expansions, partnerships, and acquisitions to strengthen their market position. For instance, in December 2021, SGS acquired Quay Pharma, a pharmaceutical R&D organization, to expand its biopharmaceutical analytical testing capabilities.
The consistent growth of API producers in the expanding pharmaceutical sector presents significant opportunities for market growth. Additionally, the increasing outsourcing of analytical testing services by pharmaceutical and biopharmaceutical companies to focus on core competencies and reduce costs is expected to drive market expansion.